Tanaka K, Tanaka M, Onodera O, Tsuji S
Department of Neurology, Brain Research Institute, Niigata University, Japan.
Rinsho Shinkeigaku. 1995 Jul;35(7):770-4.
A group of patients with paraneoplastic cerebellar degeneration (PCD) have shown to produce autoantibody to both neurons and tumor cells (anti-Yo antibody). More than 60% of these patients have shown neurological symptoms and anti-Yo antibody production before the underlying cancers were found, which suggests that the test for anti-Yo antibody is important for the early detection and treatment of cancer. Originally, anti-Yo antibody has been characterized as 1) labelling the cytoplasm of cerebellar Purkinje cells immunohistochemically, 2) binding to the 62 and 34kDa bands on immunoblots of Purkinje cell extracts, 3) being present in female patients with gynecological or breast cancers. Recently, the common binding-epitope of anti-Yo antibody has been reported as leucine-zipper protein. In order to detect the anti-Yo antibody precisely, we examined the immunohistochemical and western blot characters of the recombinant leucine-zipper protein-reactive (anti-Yo) antibody. The results were, 1) sera containing leucine-zipper protein-reactive antibody labels both cerebellar Purkinje cells but some sera might contain other antibodies together with anti-Yo that confuse the immunostaining character of anti-Yo antibody, 2) the antibody binds to 58 kDa band and sometimes co-binds to 34kDa on immunoblots of cerebellar tissue extracts. The underlying cancers are mainly adenocarcinoma in the ovary, fallopian tube, uterus, or breast but occasionally large cel lung and bile duct cancers have been found. Interestingly, a male patient had an antibody similar in character to be anti-Yo antibody immunohistochemically and on immunoblots, that did not recognize leucine-zipper protein and the underlying carcinoma was small cell lung cancer. These results suggest that 1) the diagnosis of anti-Yo antibody should be based on the antibody's reactivity with leucine-zipper protein, 2) some sera with the anti-Yo antibody label other tissues besides the Purkinje cell cytoplasm because of the co-existence of other antibodies seen immunohistochemically and on immunoblots, 3) the search for underlying cancers should not be limited to gynecological or breast carcinomas.
一组副肿瘤性小脑变性(PCD)患者已被证明会产生针对神经元和肿瘤细胞的自身抗体(抗Yo抗体)。这些患者中超过60%在发现潜在癌症之前就已出现神经症状并产生抗Yo抗体,这表明抗Yo抗体检测对于癌症的早期发现和治疗很重要。最初,抗Yo抗体的特征为:1)免疫组织化学上标记小脑浦肯野细胞的细胞质;2)与浦肯野细胞提取物免疫印迹上的62kDa和34kDa条带结合;3)存在于患有妇科或乳腺癌的女性患者中。最近,抗Yo抗体的共同结合表位已被报道为亮氨酸拉链蛋白。为了精确检测抗Yo抗体,我们检测了重组亮氨酸拉链蛋白反应性(抗Yo)抗体的免疫组织化学和蛋白质印迹特征。结果如下:1)含有亮氨酸拉链蛋白反应性抗体的血清会标记小脑浦肯野细胞,但有些血清可能除了抗Yo抗体外还含有其他抗体,这会混淆抗Yo抗体的免疫染色特征;2)该抗体在小脑组织提取物的免疫印迹上与58kDa条带结合,有时还会与34kDa条带共同结合。潜在癌症主要是卵巢、输卵管、子宫或乳腺癌,但偶尔也会发现大细胞肺癌和胆管癌。有趣的是,一名男性患者的抗体在免疫组织化学和蛋白质印迹上的特征与抗Yo抗体相似,但不识别亮氨酸拉链蛋白,其潜在癌症为小细胞肺癌。这些结果表明:1)抗Yo抗体的诊断应基于该抗体与亮氨酸拉链蛋白的反应性;2)由于免疫组织化学和蛋白质印迹中可见其他抗体的共存,一些含有抗Yo抗体的血清除了标记浦肯野细胞细胞质外还会标记其他组织;3)对潜在癌症的筛查不应局限于妇科或乳腺癌。